Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

FDA Approves Extended-Release Amantadine (GOCOVRI™) for Treatment of Dyskinesia

Statement from the Parkinson's Foundation Medical Director, Michael Okun, MD

"Today, Adamas announces FDA approval of an extended release amantadine capsule called GOCOVRI. This drug will provide a practical once a day solution for dyskinesia management and reducing "off" time. Patients who are currently well managed using multiple doses per day of generic amantadine for dyskinesia will not likely derive additional symptomatic benefits from switching to once a day dosing; however, patients experiencing side effects from amantadine may wish to discuss options with their neurologist.

Both GOCOVRI and generic amantadine use is linked to a risk of side effects such as dizziness, hallucinations or blotching on the skin of the legs.  If you are considering starting this medicine or switching to this medicine we recommend consulting with your doctor.

In an independent Parkinson's Foundation study prior to this approval, we found that generic amantadine use improved dyskinesia in patients.  However, amantadine use does have a risk of side effects including insomnia and hallucinations. GOCORVI has been designed to limit the risk of these complications and it will not carry generic amantadine's warning for insomnia."

Call our Helpline, 1-800-4PD-INFO, or visit www.GOCOVRI.com for more information.

About the Parkinson's Foundation

The Parkinson's Foundation is working toward a world without Parkinson's disease. Formed by the merger of National Parkinson Foundation (NPF) and the Parkinson's Disease Foundation (PDF), the mission of the Parkinson's Foundation is to invest in promising scientific research that will end Parkinson's disease and improve the lives of people with Parkinson's, and their families, through improved treatments, support and the best care. For more information, visit www.parkinson.org, or call (800) 4PD-INFO (473-4636).

About Parkinson's Disease (PD)

Affecting an estimated one million Americans and 10 million worldwide, PD is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression) as well as non-motor symptoms (e.g., depression and anxiety A feeling of nervousness, worried thoughts and physical distress.). There is no cure for PD and 60,000 new cases are diagnosed each year in the United States alone.

# # #

Friday, August 25, 2017
Parkinson’s Foundation Invests $500,000 in Community-Driven Clinical Research To Ease Cognition, Sleep and Fatigue in Parkinson’s
Monday, February 27, 2017

Five New Awards Address Unmet Needs

New York, NY and Miami, FL — The Parkinson’s Foundation has awarded $500,000 for translational research grants to address critical unmet needs in Parkinson’s disease.  The investments jumpstart practical solutions to ease difficulties related to cognition, fatigue and sleep, all of which are debilitating yet under-recognized symptoms in Parkinson’s.

The Parkinson's Foundation’s Moving Day® Walks Fund Local Parkinson’s Programs in 2017
Monday, February 13, 2017

$13.7 million dollars raised over five years
 

Young New Yorkers for the Fight Against Parkinson’s Committee and the Parkinson’s Foundation Celebrate the 10th Anniversary of Celebrate Spring New York Wednesday, April 5, 2017
Friday, February 10, 2017

The 10th Anniversary of Celebrate Spring New York will take place on Wednesday, April 5, 2017 at Lavo located at 39 East 58th Street between Madison and Park Avenues.  The event is hosted by the Young New Yorkers for the Fight Against Parkinson’s and the Parkinson’s Disease Foundation (PDF), a division of the Parkinson’s Foundation.

Parkinson’s Foundation Designates NewYork-Presbyterian/Columbia, Rush University Medical Centers as Parkinson’s Care ‘Centers of Excellence’
Monday, February 6, 2017

As foundation continues to invest in programs to improve the lives of Parkinson’s patients, designation of new Centers of Excellence further expand expert care network
 

Local Residents to Host Scotch & Sangria for Parkinson’s Research at Sear House in Closter, NJ, on Thursday, March 2
Monday, January 30, 2017

Proceeds From Fourth Annual Helping Hours Event Benefit Parkinson’s Foundation

Parkinson's Foundation Appoints John L. Lehr as Chief Executive Officer
Tuesday, January 10, 2017

 Lehr Charged with Advancing Foundation’s Mission to Accelerate the Science and Care for Parkinson’s Disease
 

The National Parkinson Foundation Announces Initiative to Further Define Stages of Parkinson’s Disease
Monday, January 9, 2017

Currently, there is no one definition of what it means to have advanced Parkinson’s disease
 

Initiative will support the creation of a tool to help physicians assess changes in the disease
 

Apply to the Parkinson’s Foundation People with Parkinson's Advisory Council by Monday, December 19
Monday, November 21, 2016

Are you interested in helping the Parkinson’s Foundation (PF) work toward a world without Parkinson’s? Apply to the People with Parkinson's Advisory Council by Monday, December 19.

In August, the Parkinson’s Disease Foundation and the National Parkinson Foundation merged to form the Parkinson’s Foundation. We are seeking advisors from the community to help us kick off a new and exciting era in the Parkinson’s community.

The Parkinson’s Foundation Celebrates the Life of Janet Reno
Monday, November 7, 2016

MIAMI and NEW YORK — Today we mourn the loss and celebrate the life of Janet Reno, a longtime friend of the Parkinson’s Foundation. Ms. Reno passed away at age 78 from complications of Parkinson’s disease. She was diagnosed in 1995, while still serving as the first female Attorney General of the United States. Despite her diagnosis, Ms. Reno continued in this role until 2000.

National Parkinson Foundation Expands Expert Care Network in Italy
Wednesday, November 2, 2016

MIAMI — The National Parkinson Foundation (NPF), a division of the Parkinson’s Foundation, announced today a new partnership with the Fresco Institute Italia to improve the quality of Parkinson’s care in Italy. The NPF Center of Excellence global network embodies the world’s leading Parkinson’s specialists focused on changing the course of Parkinson’s disease (PD). 

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.